← Back to Search

Markers for Primary Immunodeficiency

N/A

Waitlist Available

Research Sponsored by Meyer Children's Hospital IRCCS

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Clinical and hematological diagnosis of autoimmune cytopenia

Be younger than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up every three to six months

Awards & highlights

No Placebo-Only Group

Summary

This trial aims to better understand and find effective treatments for autoimmune cytopenias, which are common in patients with immune system disorders. Current treatments often fail, leading to high costs and health risks. The

Who is the study for?

This trial is for patients with autoimmune cytopenias, which include conditions like low platelet count, anemia, and low white blood cell count that are resistant to treatment. These patients may also have primary immunodeficiencies (PI).

What is being tested?

The study aims to identify specific early biomarkers in the immune system that can help diagnose autoimmune cytopenias and predict who will respond well to therapy.

What are the potential side effects?

Since this trial focuses on identification of biomarkers rather than testing a drug or medical intervention, there are no direct side effects associated with the interventions being studied.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have been diagnosed with a blood disorder where my immune system attacks my blood cells.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ every three to six months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~every three to six months

This trial's timeline: 3 weeks for screening, Varies for treatment, and every three to six months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Identification of specific markers

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: Identification of specific markersExperimental Treatment1 Intervention

Analysis of the immunological profile, Genetic analysis using next-generation sequencing (NGS) technology, Bioinformatic analysis, Functional studies.

0 / 1Eligibility criteria met